What is the outcome of administering anti‑D immunoglobulin to a Rh‑negative pregnant woman at 32 weeks gestation?

If an Rh-Negative Mother Skips Anti-D at 32 Weeks, She Risks Preventable Alloimmunization That Could Harm Future Pregnancies

Omitting anti-D immunoglobulin at 32 weeks significantly increases the risk of maternal Rh alloimmunization during pregnancy, which can lead to hemolytic disease of the fetus and newborn (HDFN) in subsequent pregnancies.

What Happens Without Antenatal Anti-D Prophylaxis

Risk of Alloimmunization

Without antenatal anti-D prophylaxis, approximately 1.8% of Rh-negative women carrying Rh-positive fetuses will develop anti-D antibodies during pregnancy 1. When combined with postpartum prophylaxis alone (without the antenatal dose), the overall alloimmunization rate remains at 1-2% 1. However, antenatal prophylaxis at 28 and/or 34 weeks reduces this antepartum alloimmunization rate by 90%, bringing it down to 0.1-0.2% 2.

The evidence is compelling: introduction of antenatal prophylaxis at 28 and/or 34 weeks' gestation in the United Kingdom reduced the immunization rate by another 90% beyond what postpartum prophylaxis alone achieved 2. This translated to a dramatic reduction in fetal mortality from Rh hemolytic disease from 120 per 100,000 live births to 1.5 per 100,000 by 1989 2.

Why Timing Matters

Fetomaternal hemorrhage occurs throughout pregnancy, not just at delivery:

• 7% of pregnancies show fetal cells in maternal circulation in the first trimester
• 16% in the second trimester
• 29% in the third trimester 2

The RhD antigen is well-developed by 6 weeks' gestation 2, and alloimmunization can occur with as little as 0.1 mL of fetal blood 2. Without the 28-34 week prophylaxis dose, women remain vulnerable to sensitization during the critical third trimester period when fetomaternal hemorrhage is most common.

Consequences for Current and Future Pregnancies

Current Pregnancy Impact

If alloimmunization occurs during the index pregnancy (which is uncommon but possible), the current fetus may experience:

• Mild to severe fetal anemia
• Hydrops fetalis in severe cases
• Potential fetal death 3

However, first pregnancies are typically less severely affected because antibody levels take time to rise to clinically significant titers.

Future Pregnancy Risks

The real danger is to subsequent Rh-positive pregnancies. Once a woman is alloimmunized:

• Without any anti-D prophylaxis, 17% of Rh-negative women become immunized after pregnancy with an Rh-positive infant (though actual rates may be higher due to delayed antibody detection) 2
• In subsequent pregnancies, the anamnestic response produces higher antibody levels more rapidly
• This can lead to severe HDFN requiring:
  • Intrauterine transfusions (IUT) starting as early as 18-20 weeks 3
  • Multiple IUTs throughout pregnancy
  • Preterm delivery
  • Neonatal exchange transfusions
  • Neonatal death in severe cases 3

The Evidence for Antenatal Prophylaxis

Efficacy Data

Research demonstrates clear benefit:

• A study of 830 women receiving 250 μg anti-D at 32-34 weeks showed only 0.4% developed weak anti-D antibodies (which subsequently disappeared), compared to 1.6% failure rate with postpartum prophylaxis alone 4

• Another study of 1,238 primigravidas receiving anti-D at 28 and 34 weeks showed only 6 developed antenatal immunization, compared to 32 in the control group 5

• The most recent 2024 SMFM guideline emphasizes that a mid-trimester dose reduces antepartum alloimmunization from 1.8% to 0.1-0.2% 1

Safety Profile

Anti-D administration at 32-34 weeks is safe for both mother and fetus 6, 4:

• No detectable hemolytic damage to the fetus
• No difference in neonatal bilirubin or hemoglobin levels between Rh-positive and Rh-negative infants
• No increase in adverse pregnancy outcomes 5

Clinical Algorithm When Anti-D is Missed at 32 Weeks

If a patient presents having missed the 32-week dose:

1. Administer anti-D immediately when the omission is discovered (even if late)
2. Standard dose is 300 μg (1500 IU) intramuscularly in most countries
3. Ensure postpartum prophylaxis within 72 hours of delivery if the infant is Rh-positive
4. Consider antibody screening at delivery to detect any breakthrough alloimmunization
5. In subsequent pregnancies, ensure timely antenatal prophylaxis at 28 weeks (and 34 weeks if using a two-dose regimen)

Common Pitfalls to Avoid

• Don't assume postpartum prophylaxis alone is sufficient - it only prevents alloimmunization from delivery-related fetomaternal hemorrhage, not antepartum sensitization
• Don't delay administration if the 32-week window is missed - give it as soon as possible
• Don't forget that sensitizing events (trauma, bleeding, amniocentesis) require additional doses regardless of routine prophylaxis 2
• Don't overlook obesity as a risk factor - recent case reports suggest standard dosing may be inadequate in women with BMI >35 kg/m² 7

The Bottom Line

Skipping anti-D at 32 weeks leaves the mother vulnerable to a 1.8% risk of antepartum alloimmunization that could have been reduced to 0.1-0.2% with prophylaxis 1. While this may seem like a small absolute difference, the consequences of alloimmunization—severe HDFN requiring invasive fetal interventions or causing fetal death—are devastating and entirely preventable. The evidence from decades of population-level data shows that antenatal prophylaxis has dramatically reduced Rh-related fetal mortality 2, making it one of the most successful preventive interventions in obstetrics.